DrugPatentWatch Database Preview
Details for Patent: 6,479,500
Join the DrugPatentWatch Referral Program Get access to a free drug patent landscape report or a free one-month subscription
Which drugs does patent 6,479,500 protect, and when does it expire?
Patent 6,479,500 protects LONSURF and is included in one NDA.
This patent has fourteen patent family members in eleven countries.
Summary for Patent: 6,479,500
Title: | Agents for alleviating side effects |
Abstract: | The present invention provides an agent for alleviating side effects caused by use of an anti-tumor agent, which contains 5-chloro-6-(2-iminopyrrolidin-1-yl)methyl-2,4(1H,3H)-pyrimidi nedione (1) represented by formula (1): ##STR1## or a pharmaceutically acceptable salt thereof. The 5-chloro-6-(2-iminopyrrolidin-1-yl)methyl-2,4(1H,3H)-pyrimidinedione or a pharmaceutically acceptable salt thereof exhibit an inflammatory-suppressing action in the digestive tract and advantageously alleviate diarrhea and loss of body weight concomitant with administration of a chemical for treating cancer without suppressing the anti-tumor effect. Thus, the compounds of the present invention are of great value as agents for alleviating side effects caused by use of an anti-tumor agent, which enable not only the chemotherapy to be continuedly carried out, but also the body exhaustion to be effectively prevented. |
Inventor(s): | Fukushima; Masakazu (Hannou, JP), Yamamoto; Noriyuki (Sayama, JP), Suzuki; Norihiko (Hidaka, JP) |
Assignee: | Taiho Pharmaceutical Co., Ltd. (Tokyo, JP) |
Application Number: | 09/701,041 |
Patent Claim Types: see list of patent claims | Use; |
Drugs Protected by US Patent 6,479,500
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Taiho Oncology | LONSURF | tipiracil hydrochloride; trifluridine | TABLET;ORAL | 207981-001 | Sep 22, 2015 | RX | Yes | No | Start Trial | Start Trial | TREATMENT OF PATIENTS WITH METASTATIC COLORECTAL CANCER WHO HAVE BEEN PREVIOUSLY TREATED WITH FLUOROPYRIMIDINE-, OXALIPLATIN- AND IRINOTECAN-BASED CHEMOTHERAPY, AN ANTI-VEGF BIOLOGICAL THERAPY, AND IF RAS WILD-TYPE, AN ANTI-EGFR THERAPY | Start Trial | ||||
Taiho Oncology | LONSURF | tipiracil hydrochloride; trifluridine | TABLET;ORAL | 207981-002 | Sep 22, 2015 | RX | Yes | Yes | Start Trial | Start Trial | TREATMENT OF PATIENTS WITH METASTATIC COLORECTAL CANCER WHO HAVE BEEN PREVIOUSLY TREATED WITH FLUOROPYRIMIDINE-, OXALIPLATIN- AND IRINOTECAN-BASED CHEMOTHERAPY, AN ANTI-VEGF BIOLOGICAL THERAPY, AND IF RAS WILD-TYPE, AN ANTI-EGFR THERAPY | Start Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
Foreign Priority and PCT Information for Patent: 6,479,500
Foriegn Application Priority Data | ||
Foreign Country | Foreign Patent Number | Foreign Patent Date |
Japan | 11-77579 | Mar 23, 1999 |
PCT Information | |||
PCT Filed | March 16, 2000 | PCT Application Number: | PCT/JP00/01607 |
PCT Publication Date: | September 28, 2000 | PCT Publication Number: | WO00/56337 |
International Family Members for US Patent 6,479,500
Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
---|---|---|---|---|---|
Austria | 323494 | Start Trial | |||
Australia | 3192800 | Start Trial | |||
Australia | 772486 | Start Trial | |||
Canada | 2331737 | Start Trial | |||
China | 1144587 | Start Trial | |||
China | 1297350 | Start Trial | |||
>Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |